Cologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. FDX
6. IBM
7. MU
8. ACN
9. USO
10. NVDA

Go back to Cologuard® revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests

Exact Sciences (EXAS) PT Raised to $45 at Canaccord Genuity Following 2Q

July 26, 2017 10:11 AM EDT

Canaccord Genuity raised its price target on Exact Sciences (NASDAQ: EXAS) to $45.00 (from $42.00) while maintaining a Buy rating. 2Q revenues of $57.6M came in ahead of the Street's $49.7M. EXAS holds $483M of cash and Cologuard is now covered by 235M... More

Exact Sciences (EXAS) Tops Q2 EPS by 8c, Sales Beat; Raises Cologuard Outlook

July 25, 2017 4:10 PM EDT

Exact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.27), $0.08 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $57.6 million versus the consensus estimate of $49.84 million.

"As patient and physician demand for Cologuard continues to grow, momentum is increasing toward... More